Cereno Scientific

5.81 SEK

+0.26 %

Less than 1K followers

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

+0.26 %

-10.55 %

-16.95 %

-22.60 %

-36.14 %

+19.49 %

+217.91 %

+218.96 %

-3.43 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Market cap

1.81B SEK

Turnover

4.15M SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

27.5

2026

Interim report Q1'26

17.6

2026

General meeting '26

26.8

2026

Interim report Q2'26

All

Webcasts

Press releases

3rd party

ShowingAll content types

Press releaseyesterday

Cereno Scientific to Participate at BIO-Europe Spring and LSX World Congress Europe 2026 on March 23-26 in Lisbon

Cereno Scientific

Regulatory press release2/27/2026, 6:45 AM

Cereno Scientific Publishes Year-end Report for 2025 (January 1 - December 31, 2025)

Cereno Scientific

Third party research2/20/2026, 10:31 AM

Cereno Scientific: CMD reaffirms shifting focus to clinical delivery - Edison

Cereno Scientific’s recent capital markets day (CMD) centered on CS1’s progression from early clinical validation into Phase IIb development, a key inflection for the investment thesis. Supported by key opinion leader (KOL) and patient perspectives, ...

Cereno Scientific

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release2/4/2026, 9:00 AM

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease

Cereno Scientific

Press release2/3/2026, 6:45 AM

Cereno Scientific Provides Update on Expanded Access Program for CS1 - initial learnings expected in Q1 2026

Cereno Scientific

Press release2/2/2026, 1:00 PM

Cereno Scientific Announces Program and Speakers for the Capital Markets Day on February 5, 2026

Cereno Scientific

Press release1/28/2026, 12:02 PM

Cereno Scientific to Present CS014 Data and Participate in Panel at Scientific Conference PVRI 2026 Dublin

Cereno Scientific

Press release1/16/2026, 6:45 AM

Cereno Scientific: Invitation to Capital Markets Day 2026

Cereno Scientific

Press release1/14/2026, 12:15 PM

Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases

Cereno Scientific

Third party research1/13/2026, 6:18 AM

Cereno Scientific: Entering a value inflection phase - Edison

We refresh our investment case for Cereno Scientific as the company enters a key value inflection period, with its lead asset CS1 expected to initiate a Phase IIb study in Q226, followed by Phase II development of CS014 shortly thereafter. With the FDA...

Cereno Scientific

Regulatory press release1/8/2026, 9:45 AM

Cereno Scientific Receives approximately SEK 5 million Through Exercise of 728,957 Warrants by Arena Investors, LP

Cereno Scientific

Press release12/18/2025, 1:50 PM

Cereno Scientific's Board of Directors and Management Enter Lock-up Agreements

Cereno Scientific

Press release12/18/2025, 9:00 AM

Cereno Scientific to Host Capital Markets Day on February 5, 2026

Cereno Scientific

Press release12/12/2025, 6:45 AM

Cereno Scientific to Attend JPM Week and Biotech Showcase in San Francisco, US, on January 12-18, 2026

Cereno Scientific

Regulatory press release12/8/2025, 9:25 PM

Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)

Cereno Scientific

Press release12/3/2025, 7:00 AM

Cereno Scientific to Present New Data of CS014 at the Pharmacology 2025 on December 15-18

Cereno Scientific

Regulatory press release11/30/2025, 9:17 AM

Correction: Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027

Cereno Scientific

Press release11/28/2025, 6:31 PM

Cereno Scientific: Major shareholders and new investors back the Company's long-term strategy with equity investment at a premium

Cereno Scientific

Regulatory press release11/28/2025, 6:30 PM

Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027

Cereno Scientific

Regulatory press release11/27/2025, 6:30 AM

Cereno Scientific Publishes Interim Report for Q3 2025 (July 1 - September 30, 2025)

Cereno Scientific

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.